Associated Papers
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.
Frank S et al.
Biorxiv : the Preprint Server for Biology, 2025
39071291 (PubMed )
Supplement: media-1.xlsx › SU2C-I
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T et al.
International Journal of Clinical Oncology, 2022
Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
Izawa M et al.
Iju Case Reports, 2021
Select a paper to view details